pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
1 A
ntibacterial Resistance Leadership Group (ARLG)  
P
erformance of Nucleic Acid Amplification Tests for the Detection of Neisseria gonorrhoeae 
and Chlamydia t rachomatis  in Extra genital  Sites   
(pNAAT ) 
P
rotocol Number:  
ARLG_pNAAT -Yr3 
F
unding Sponsor:  
National Institute of Allergy and Infectious Diseases (NIAID)  
F
unding Mechanism: 5UM1AI104681  
P
rotocol Date:  December 4th, 2017 
Protocol Version:  4.0 
Principal Investigator  Dr. Jeffrey D. Klausner, MD, MPH  
[STUDY_ID_REMOVED]
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
2  
Signature Page  
 
 
The signature below documents the review and approval of this protocol and provides the necessary 
assurances that this study will be conducted according to the protocol, including all statements regarding 
confidentiality , and according to  national, regional, and local legal and regulatory requirements.  
 
 
     
Site Principal Investigator Name (Print)   
   
   
Signature   Date  
 
  
  
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
3  
ARLG GC Protocol  Team  Roster  
All questions concerning this protocol should be sent via email to arlg.gc@mc.duke.edu .  The appropriate 
team member will respond to questions via email, generally within 24 hours (Monday -Friday).
Protocol Chair  
 
Jeffrey D. Klausner, MD, MPH  
Professor of Medic ine and Public Health  
University of California, Los Angeles  
10833 Le Conte Avenue  
Los Angeles, CA 90095 
Phone:  310-267-0409  
Email:  JDKlausner@mednet.ucla.edu  
 
Project Leader  
 
Zoe Sund  
Duke Clinical Research Institute  
2400 Pratt Street  
Durham NC 27705  
Phone:  919-428-1007  
Email:  zoe.sund @duke.edu   
 
Statistician s 
 
Scott  Evans,  PhD 
Harvard School  of Public  Health  FXB 513 
651 Huntington Avenue  
Boston,  MA 02115- 6017  
Phone:  617-432-2998  
Email:  evans@sdac.harvard.edu  
 
Lauren Komarow, MSc  
Harvard School  of Public  Health  FXB 549A  
651 Huntington Avenue  
Boston,  MA 02115- 6017  
Phone:  617-432-3233  
Email:  lkomarow@sdac.harvard.edu   
 
Thuy Tran, MSc  
Harvard School of Public Health FXB 608  
651 Huntington Avenue  
Boston, MA 02115- 6017  
Phone: 617- 432-7523  
Email: ttran@sdac.harvard.edu  
 
 
 
 Protocol Clinician s 
 
Sarah Doernberg, MD, MAS 
Division of Infectious Diseases  
University of California,  San Francisco  
513 Parnassus Ave, Box 0654  
San Francisco, CA 94143  
Phone: 415- 502-5548  
Email: sarah.doernberg@ucsf.edu  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
4 Table of Contents  
L
IST OF ABBREVIATION S AND DEFINITIONS  ............................................................................................. 6  
1.0 BACKGROUND AND SCIENTIFIC RATIONALE  .............................................................................. 9  
1.1 BACKGROUND INFORMATION  ................................................................................................................... 9  
1.2 SCIENTIFIC RATIONALE  ............................................................................................................................ 9  
2.0 OBJECTIVES  ....................................................................................................................................... 11 
2.1 PRIMARY OBJECTIVE  ............................................................................................................................. 11 
2.2 SECONDARY OBJECTIVES  ...................................................................................................................... 11 
2.3 OUTCOME MEASURES  ........................................................................................................................... 11 
3.0 STUDY DESIGN  .................................................................................................................................. 14 
3.1 STUDY DESIGN  ....................................................................................................................................... 14 
3.2 INCLUSION CRITERIA  .............................................................................................................................. 15 
3.3 EXCLUSION CRITERIA  ............................................................................................................................ 15 
4.0 STUDY PROCEDURES  ...................................................................................................................... 16 
4.1 RECRUITMENT PLAN .............................................................................................................................. 16 
4.2 SCREENING  ............................................................................................................................................ 16 
4.3 ENROLLMENT  ......................................................................................................................................... 16 
4.6 FOLLOW -UP VISIT ................................................................................................................................... 17 
5.0 DEVICE MONITORING  ....................................................................................................................... 17 
5.1 SPECIMEN COLLECTION DEVICE MONITORING  ..................................................................................... 17 
5.2 LABORATORY DEVICE MONITORING  ...................................................................................................... 17 
6.0 STATISTICS ......................................................................................................................................... 18 
6.1 STUDY DESIGN  ....................................................................................................................................... 18 
6.2 ENDPOINTS  ............................................................................................................................................ 18 
6.3 SAMPLE SIZE .......................................................................................................................................... 18 
6.4 RANDOMIZATION OF SWABS  .................................................................................................................. 19 
6.5 MONITORING  .......................................................................................................................................... 19 
6.6 ANALYSES  .............................................................................................................................................. 20 
7.0 QUALITY CONTROL  .......................................................................................................................... 23 
7.1 QUALITY CONTROLS AND STUDY MONITORING  .................................................................................... 23 
7.2 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA ....................................................................... 23 
8.0 ETHICS / PROTECTION OF HUMAN SUBJECTS  .......................................................................... 23 
8.1 ETHICAL STANDARDS  ............................................................................................................................. 23 
8.2 INSTITUTIONAL REVIEW BOARD AND INFORMED CONSENT  .................................................................. 23 
8.3 SUBJECT CONFIDENTIALITY  ................................................................................................................... 23 
8.4 SPECIMEN HANDLING  ............................................................................................................................. 24 
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
5 9.0 DATA HANDLING AND RECORD KEEPING  .................................................................................. 24 
9.1 DATA COLLECTION  ................................................................................................................................. 24 
9.2 INSPECTION OF RECORDS  ..................................................................................................................... 24 
9.3 RETENTION OF RECORDS  ...................................................................................................................... 24 
9.4 CONFIDENTIALITY  ................................................................................................................................... 25 
10.0  PUBLICATION POLICY  ...................................................................................................................... 25 
APPENDIX A - SCHEDUL E OF EVENTS ...................................................................................................... 30 
pNAAT           Version 4.0  
     December 4th, 2017  
6 L
ist of Abbreviations  and Definitions  
ARLG  Antibacterial Resistance Leadership Group  
ASIS  Anatomic Site Infection Status  
CDC  Center for Disease Control and Prevention  
CFR Code of Federal Regulations  
CT Chlamydia trachomatis  
DCRI  Duke Clinical Research  Institute  
DNA  Deoxyribonucleic acid  
Equivocal  Final e quivocal result from nucleic acid amplification test , as determined by  
manufacturer’s guidance. This means the test was run and the result was neither  
positive nor negative  
FDA Food and Drug Administration  
HIV Human immunodeficiency virus  
ICMJE  International Committee of Medical Journal Editors  
ID Identification  
IFU Instructions for Use 
Indeterminate  Anatomic site infected standard cannot be determined as positive or negative  
IRB Institutional Review Board  
ISRC  Independent Study Review Committee 
LGBT  Lesbian, gay, bisexual and transgender  
NAAT  Nucleic acid amplification test  
Negative ( -) 
NAAT reading  Result from the nucleic acid amplification test is negative  
NR This means no  test was run and there is no result  
NPA Negative percent agreement  
NPV Negative predictive value  
NG Neisseria gonorrh oeae 
NIH National Institutes  of Health  
OHRP  Office of Human Research Protections  
Positive (+) 
NAAT reading  Result from the nucleic acid amplification test  is positive  
PPA Positive percent agreement  
PPV Positive predictive value  
PI Principal Investigator  
RNA  Ribonucleic acid  
pNAAT           Version 4.0  
     December 4th, 2017  
7 rRNA  Ribosomal ribonucleic acid  
SDMC  Statistical and Data Monitoring Center  
STD Sexually transmitted diseases  
WHO  World Health Organization  
pNAAT           Version 4.0  
     December 4th, 2017  
8 P
rotocol Synopsis  
P
rotocol Title:  Performance of Nucleic Acid Amplification Tests for the Detection of 
Neisseria gonorrhoeae and Chlamydia t rachomatis  in Extra genital Sites  
Study Design:  A cross- sectional , single visit  study  to evaluate the diagnostic accuracy of  
nucleic acid amplification tests  for detection of Neisseria gonorrhoeae and 
Chlamydia trachomatis from pharyngeal and rectal sites  
Primary Study 
Objectives:  For each nucleic acid amplification assay, estimate the positive percent 
agreement (PPA)  and negative percent agreement (NPA)  for detecting:  
•Neisseria gonorrhoeae in rectal swabs
•Neisseria gonorrhoeae in pharyngeal swabs
•Chlamydia trachomatis  in rectal swa bs
•Chlamydia trachomatis  in pharyngeal swabs
Study Population  Patients presenting to an outpatient clinic for sexually transmitted disease 
(STD) testing for  Neisseria gonorrhoeae and Chlamydia t rachomatis  
infections  
Number of 
subjects  Up to 3,000 
Study  duration  Approximately 12 to 24 months  
Number of sites  Up to 10 clinical sites  (as needed)  
Clinical Samples  Pharyngeal and rectal swabs  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
9 1.
0 Background and Scientific Rationale 
1.
1 Background Information 
N
ucleic acid amplification tests (NAATs) have become the gold standard for diagnosing 
Neisseria gonorrhoeae (NG) and Chlamydia t rachomatis  (CT) infections in the uro genital 
tract but are not currently approved by the Food and Drug Administration (FDA) for use in 
extragenital sites, including the pharynx and the rectum.  
T
he goal of this study is to determine the diagnostic accuracy of the following 3 NAAT 
platforms  for the detection of NG and CT from the pharynx and the rectum:   
•Company 1 Assay [C ompany 1 ] 1
•Company 2 Assay [Company 2 ] 2
•Company 3 Assay [Company 3] 3
T
he assays being evaluated are intended for the direct qualitative detection of Chlamydia 
trachomatis and/or  Neisseria gonorrhoeae in rectal or pharyngeal clinician -collected 
swabs from symptomatic or asymptomatic male or female patients . 
1.
2 Scientific Rationale 
I
nfections due to NG and CT  are a major public health threat. The World Health 
Organization (WHO)  estimated more than 100 million new  worldwide cases for each of 
NG and CT in 2008.4  In the US  alone, there were  333,000 NG and 1.4 million  CT 
genitourinary  infections  in the year 2013.5 Over the past 15 years, researchers have 
demonstrated an important burden of  NG and CT  infection in extragenital sites - the 
pharynx and rectum.  Most CT and NG  infections are asymptomatic, but infection can lead 
to serious sequelae, including infertility, chronic pelvic pain,  adverse obstetrical 
outcomes,  increased risk of human immunodeficiency virus ( HIV) acquisition, and 
disseminated infection .6-9 In addition to threats to individual health, there has been 
growing concern over antibiotic  resistance, and in 2013, the US Centers for Disease 
Control and Prevention (CDC) classified drug- resistant NG as one of the three urgent -
level resistant bacteria.  Improved detection of extragenital NG is thought to be a crucial 
component of adequate treatment and thus prevention of further resistance.10  
C
urrently, the CDC recommends the use of NAATs for NG  and CT  screening and 
diagnosis in the genitourinary  tract due to superior sensitivity compared to traditional 
culture methods.11 The sensitivity and specificity of commercially available NAATs for the 
detection of  genitourinary  NG and CT  infection is estimated to be between 90 -100% .12  
CDC also recommends the use of NAATs for extragenital sites .11 Due to widespread use 
and interest in these tests for extragenital NG and  CT infections, multiple  studies have 
examined the test characteristics of NAAT tests in comparison to culture and to additional NAAT platforms  (see Table  1). For diagnosis of CT, reported sensitivities are 80- 100% 
(pharyngeal) and 46- 100% (rectal), with s ignificant variation by platform tested.
13-19 
Reported specificities are >99% for pharyngeal site and 89- 100% for the rectum. For 
diagnosis of NG, reported sensitivities are 72- 100% (phary ngeal) and 75- 100% (rectal), 
again with variation by platform .13,14,16-18 ,20,21 Reported specif icities are 72 -100% 
(pharyngeal) and 95- 100% (rectal).   
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
10 Table 1.  Prior Studies of extragenital testing for chlamydia and gonorrhea.  
Screening test  Sensitivity/specificity * by specimen type  (%) 
Pharyngeal  Rectal  
Neisseria gonorrh oeae 
 Bachmann LH et al,  201016 100 / 96.2 100 / 95.5 
 Cosentino LA et al,  201217 76 / 100 
 Moncada J et al,  200919 78.3 / 99.8 
 Ota KV et al, 200913 95 / 99.6 100 / 100 
 Schachter J et al, 200814 84.3 / 99.4 93.2 /  99.7 
100/100  100/100  Walsh A et al, 201122 
 Goldenberg SD et al., 201223 91.1 / 100 
 Cosentino LA et al, 201524 100 / 100 
Chlamydia  trachomatis  
 Bachmann LH et al,  201016 100 / 88.8 
 Cosentino LA et al,  201217 100 / 99.8 
 Moncada J et al,  200919 71.2 / 99 
 Ota KV et al, 200913 100 / 99.2 100 / 98.7 
 Schachter J et al,  200814 100 / 99.6 93.5 / 97.7 
 Goldenberg SD et al., 201223 86 / 99.2 
 Cosentino LA et al, 201524 96.6 / 99.7 
*Sensitivity and specificity as reported by authors , each using unique definitions for the reference standard. As
discussed below, we will be using positive percent agreement (PPA) and negative percent agreement (NPA) for
these calculations.
Despi
te the CDC recommendations, at this time,  there are no FDA -cleared commercial 
NAAT tests  for the detection of pharyngeal and rectal NG or CT infection.  The FDA -
clearance of such assays would increase the availability  and uptake and subsequently  
lead to improved screening and enhanced control of  NG and CT  extragenital  infections.   
The current proposed study will help provide the data required for FDA consideration to 
clear such assays for marketing.  
Becaus
e of the multi -site nature of the ARLG, its strong laboratory network and inclusion 
of investigators with expertise in NG and CT  detection and treatment, the ARLG is well-
positioned to conduct such a study.  C urrent commercial assays are “dual” assays and 
include targets for both NG and CT, so the goal of this study will be to evaluate the 
diagnostic accuracy for detection of both organisms at extragenital sites.    
The m
olecular targets of the three NAAT platforms that will be tested differ, which will 
allow for comparative evaluation.25  
•Company 1 Assay  (Company 1) [redacted] 1
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
11 •Company 2 A ssay (Company 2) [redacted] 2
•Company 3 Assay (Company 3) [redacted] 3
Additional testing using the tiebreaker test [redacted] will be performed in cases  of 
discordant
 results (see Section 3.5). This test utilizes [redacted] to identify the presence 
of
 the organism of interest in the clinical sample. [redacted]. Though the diagnostic 
ac
curacy of these assays for extragenital infections  has not previously been evaluated, 
studies evaluating the performance of these assays for confirmation of other NAATs 
suggest excellent concordance.28-31 
2.0 Objectives  
2.1 Primary Objective  
For eac
h NAAT , estimate the PPAs  and NPAs  for detecting:  
•Neis
seria gonorrhoeae in rectal swabs
•Neisseria gonorrhoeae in pharyngeal swabs
•Chlamydia trachomatis  in rectal swabs
•Chlamydia trachomatis  in pharyngeal swabs
2.2 Secondary Objectives  
2.2.1  G
lobal analyses: 
For eac
h NAAT, positive predictive values  (PPVs) , negative predictive values  (NPVs), 
positive likelihood ratios, negative likelihood ratios, and sensitivity analyses will be 
calculated for detecting:  
•Neisseria gonorrhoeae in rectal swabs
•Neisseria gonorrhoeae in pharyngeal swabs
•Chlamydia trachomatis  in rectal sw abs
•Chlamydia trachomatis  in pharyngeal swabs
2.2.2  S
ubgroup analyses:  
For eac
h NAAT , to estimate the PPAs , NPAs , PPVs , and NPVs  for detection of NG and 
CT from rectal and pharyngeal swab s pecimens  by sex and by anatomic site- specific 
symptom status . 
2.3 Outcome Measures  
The anatom
ic site infected status (ASIS) will be determined for each anatomic site 
(pharyngeal and rectal) and each organism (NG and CT), as shown below  in Table 2. 
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
12 P
ossible ASIS outcomes are: 
•Infected
•Not infected
•Indeterminate
•Invalid, exclude from analysis
The anatomic s ite is c onsidered to be infected i f both of t he reference test r esults are 
positive. T he anatomic s ite is c onsidered to be not i nfect ed when both reference test 
results ar e negative. I f there is d iscordanc e between t he reference tests, an add itional 
NAAT w ill be don e as a tie breaker. I n this c ase, agr eement of 2/ 3 of t he reference NAATs 
will d etermine the ASIS. If t wo tests ar e equivocal or o ne equivocal a nd one not r un, the 
third test r esult will s tand a s the ASIS i f pos itive or ne gative. I f two tests ar e not r un, the 
ASIS will b e considered invalid a nd will b e excluded f rom t he analysis. All possible 
combinations are shown i n Table 2. The tiebreaker t est w ill be run b y the lab if an y NAAT 
is not concordant with the others and interpreted only in the case of discordant results 
between the two planned reference tests for each assay.  [redacted]. 
To determine the ASIS, the test result for each respective site (pharyngeal or rectal) and 
each organism (NG or CT) for each NAAT platform will be us ed.  Possible outcomes for 
each ass ay are:  
•Company 1 Assay (Company 1)1: Not detected, detec ted, invalid (sample  
processing control or sample adequacy control failed), error (probe check control  
failed), or no result (insufficient data was collected, e.g. test aborted). Initial invalid,  
error, or no result tests will be repeated. If the repeat tes t returns invalid, error, or no  
result, the final result will be considered an inv alid and will be categorized as  no result 
(NR) for the ASIS determination and statistical analyses  below. If the repeat test 
returns  not detected (negative) or detected (positive),  this will be the result used for 
the ASIS determination and statistical analyses.
•Company 2 Assay (Company 2)2: Negative, positive, equivocal (result between 
positive and negative), invalid (run status  is FAIL or other technical failure),  or error 
(sample was not tested due to an error detec ted by the instrument). Initial equivocal, 
invalid, and error test results will be repeated. If the repeat test result returns 
equivocal, the final test result will be considered an equivoc al test result for the ASIS 
determination and statistical analyses below. If the repeat test result returns invalid or 
error, the final test result will be c ategorized as equivocal if the initial test was 
equivocal and as no result (NR) if the initial test was invalid or error for the ASIS 
determination and statistical analyses below. If the repeat test returns negative or 
positive, this will be the result considered for the ASIS determination and statistical 
analyses.
•Company 3 Assay (Company 3 )3: For NG, possible results are positive
(detected, with cycle number less than or equal to the assay cut-o ff), negative ( no 
evidence of amplification or cycle number greater than the assay cut-o ff), and error.  
An equivocal interpretation does not apply. For CT, possible res ults are positive
(detected, with cycle number less than or equal to the assay cut-o ff), negative (no  
evidence of amplification), equivocal (c ycle number beyond the assay cut-o ff), and  
error. A sample with initial interpretation of error (both CT and NG) or eq uivocal (C T 
only) will be retested. If the repeat tes t returns negative or positive, this will be the  
result considered for the ASIS determination and statistical analyses. If the repeat
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
13 test result is equivocal  (CT only), the final test result will be considered equivocal for 
the ASIS determination and statistical analyses  below.  If the repeat test result is 
error, the final test result will be categorized as no result  (NR) for the ASIS 
determination and statistical analyses below  if the initial test result was error and as 
equivocal  if the initial test result was equivocal (CT only) .  
•Tiebreaker assay: Tiebreaker Assay (Company 4):  Negative, positive, equiv ocal 
(result between negative and positive ranges), invalid (run status is FAIL or other 
technical failure),  or error (s ample was not tested due to an error detected by the 
instrument). Initial equivocal, invalid and error test res ults will be repeated. If the  
repeated test result is equivocal, it will be considered an equiv ocal test result for the  
ASIS determination and statistical analyses below. If the repeat test result returns  
invalid or error, the final test result will be categorized as equivocal if the initial test  
was equivocal and as no result (NR) if the initial test was invalid or error for the ASIS  
determination and statistic al analyses below. If the repeat test returns negative or  
positive, this will be the res ult considered for the ASIS determination and statis tical 
analy ses.
       Table 2 . Determination of the Anatomic Site Infected Standard  
Comparator NAAT 1 
Result  Comparator NAAT 2 
Result  Tiebreaker NAAT 
Result  Anatomic Site Infection 
status 
+ + Not indicated  Infected  
+ - + Infected  
+ E* + Infected  
+ NR** + Infected  
+ - - Not infected  
+ - E Indeterminate  
+ - NR Indeterminate  
+ E - Indeterminate  
+ E E Infected  
+ E NR Infected  
+ NR - Indeterminate  
+ NR E Infected  
+ NR NR Invalid,  
remove from analysis  
- - Not indicated  Not infected  
- + - Not infected  
- E - Not infected  
- NR - Not infected  
- + + Infected  
- + E Indeterminate  
- + NR Indeterminate  
- E + Indeterminate  
- E E Not infected  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
14 - E NR Not infected  
- NR + Indeterminate  
- NR E Not infected  
- NR NR Invalid,  
remove from analysis  
E + + Infected  
E - - Not infected  
E + - Indeterminate  
E + E Infected  
E + NR Infected  
E - + Indeterminate  
E - E Not infected  
E - NR Not infected  
E NR + Infected  
E NR - Not infected  
E NR E Indeterminate  
E NR NR Invalid,  
remove from analysis  
NR + + Infected  
NR - - Not infected  
NR NR Not indicated  Invalid,  
remove from analysis  
NR + - Indeterminate  
NR + E Infected  
NR + NR Invalid,  
remove from analysis  
NR - + Indeterminate  
NR - E Not infected  
NR - NR Invalid,  
remove from analysis  
NR E + Infected  
NR E - Not infected  
NR E E Indeterminate  
NR E NR Invalid,  
remove from analysis  
*E = equivocal result
**NR = no result. This can occur either because the test result was invalid or because the test could not be run
(e.g. too little sample, improperly shipped, no sample received) .
3.0 S
tudy Design  
3.1 S
tudy Design  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
15 This will be a cross -sectional , single visit  study evaluating the performance of three 
commercial NAATs to detect  NG and CT  in the rectum and pharynx .1,2,32 ,33  A fourth 
NAAT is being used as a tiebreaker.26,27 We are not evaluating the performance of this 
fourth NAAT.   
The study will include specimens collected from  adult subjects  seeking sexually 
transmitted disease ( STD) testing at  the participating clinics , which include clinics 
focused on sexually transmitted diseases,  women’s health, student health,  family 
planning clinics, and clinics  specializing in lesbian, gay, bisexual, and transgender  
(LGBT)  health .  Potential subjects will be identified, assessed for eligibility and 
approached for informed consent.  Both symptomatic and asymptomatic individuals will 
be included in the study population.  
The s
tudy will enroll up to 3,0 00 subjects who will have four pharyngeal  and four rectal 
swabs collected as part of a one- time study visit.  E ach manufacturer will have specific 
collection kit and transport media.  Additional data collection w ill include , but is not limited 
to, eligibility screening questions, gender, age, and patient report of relevant pharyngeal , 
rectal , or other relevant  symptoms , and swab collection completeness . Subjects will be 
classified as symptomatic or asymptomatic for each anatomic site. Results of testing at 
other anatomic sites and results of clinical testing will not be available.   
Eac
h swab will be used for a specific NAAT , which will be run at one of the two reference 
testing laboratories .  The ASIS will be defined by the results of the two other  nucleic acid 
amplification tests , and a tiebreaker test  (if necessary) , as shown in Table 2. Each 
anatomic site will be considered in isolation.  
Wh
en accrual  is complete,  the study  will be closed and an analysis plan will be enacted 
to finalize the database for analysis.  
3.2 I
nclusion Criteria  
a)Attending a participating clinic for evaluation of STDs
b)≥18 years of age at date of screening
c)Able and willing to provide informed consent
d)Willing to comply with study procedures , including collection of 4 swabs each
from the pharynx and rectum  for NG and CT test ing
NO
TE:  Male, female, and  transgender individuals will be included, and both symptomatic 
and asymptomatic individuals  will be included.  
3.3 Ex
clusion Criteria  
a)Rec
eipt of any systemic antibacterial  drug in the past 14 days
b)Receipt of myelosuppressive chemotherapy in the past 30 days
3.4 Nucleic Acid Amplification T ests (NAAT s) 
Th
is study will evaluate three distinct NAAT platforms. The selected platforms25 are: 
Company 1 Assay (Company 1) [redacted] 1
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
16 Company 2 Assay (Company  2) [redacted].2
•Company 3 Assay (Company 3) [redacted] 3
3.5 Tiebreaker A ssay 
In case of disagreement between reference NAAT results, a tiebreaker as say will be 
performed. This assay will use [redacted] (see Section 2.3). [redacted]    
4.0 Stu
dy Procedures  
4.1 Rec ruitment Plan  
Th
is study will enroll  up to 3,000 partic ipants who are seeking STD testing at one of the 
participating clinics . Potential subjects will be recruited without regard for risk behavior, 
symptom status, or gender . Participating clinics may include those designed f or STD 
screening and management, family planning, student health, women’s health, HIV 
management , and clinics focusing on the LGBT population.  
4.2 Sc
reening  
Participants  will be recruited from clinical sites performing routine ST D testing.  It is 
assumed that  individual s presenting for routine ST D testing at the participating clinic s are 
at risk for such infections.  Each person will undergo screening for eligibility and, if 
eligible, will be approached for oral informed consent .   
4.3 Enrollment 
Once enrolled,  eight swabs will be taken:  four swabs will be taken from the pharyn x and 
four swabs will be taken from the rect um in addition to any swabs taken as part of routine 
clinical care. The swabs collected for routine clinical care will be taken first. The order of 
the research swabs will be randomized per subject to account for the possibility that  the 
yield of the swab is affected by previous swabs at the same anatomic site. The swabs will 
be stored and transported per manufacturer guidelines. Results of th ose NAATs will not  
be reported back to the treating clinician for clinical purposes.   
Dat
a collection will include , but is not limited to,  assessment of signs and symptoms of 
rectal and/or pharyngeal  infection, as well as socio- demographic information such as age 
(not date of birth) , race, ethnicity and gender , and swab collection completeness .   
4.5 I
ncomplete Swab C ollection  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
17 W
hile required as an inclusion criteria for a potential subject to agree to both pharyngeal 
and rectal swabs, if only one anatomic site is swabbed after enrollment for whatever 
reason, and all four swabs are completed for that anatomic site, those swabs fo r that 
anatomic site will be included in the analysis. If fewer than four swabs at a site are 
completed, that anatomic site (and swab results)  will be excluded from the analysis.  
4.
4 Subject Withdrawal and Replacement  
S
ubjects may voluntarily withdraw their consent for study participation at any time and for 
any reason, without penalty.  The primary reason for withdrawal from the study will be 
recorded on the Study Status case report  form.  Subjects who withdraw will not be 
replaced.  
4.
5 Study Discontinuation  
T
his study  may be terminated at any time by the Principal  Investigator  (PI) in 
consultation  with the Antibacterial Resistance Leadership Group ( ARLG ) and/or  the 
National Institutes of Health ( NIH).   
4.6 F
ollow -up Visit  
There will not be a follow -up visit as part of this study.  Subjects will continue with routine 
clinical care as directed by their medical providers.  
4.
7 Central Laboratory Procedures  
T
here will be two reference testing laboratories, w hich will divide the processing 
and running of the NAAT s for th e study. Each clinical study site will be assigned 
to send swabs to one of the two laboratories. Swabs will be processed and run at 
the reference testing laborator ies according to each manufacturer’s Instructions 
for Use (IFU). Initial equivocal , invalid, or otherwise undetermined results will be 
repeated per manufacturer’s guidelines before determining whether the result will 
be classified as positive, negative, equivocal, or no result . One of the reference 
testing laboratories will be responsible for running all of the tiebreaker assays, regardless of  the location of original study site.  
T
he reference testing laborator ies will receive  training for each of the study 
platforms from a representative from each of the manufacturers , in order to 
ensure adherence to the manufacturer’s IFU procedures .  
5.0 D
evice Monitoring 
5.1 S pecimen C ollection Device M onitoring 
Any c
omplications with the specimen collection process, including device failure, 
significant patient discomfort , or inability to collect specimen, will be reported on the 
specimen collection case report form.  
5.2 Labor atory Device Monitoring  
T
he reference testing laborator ies will maintain a log of all unanticipated device- related 
complications  leading to no test, such as absence of transport media, quantity not 
sufficient, specimen transport collection system  damage or incorrect transport system.  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
18 6.0 Statistic s 
6.1 
6.2 Study D esign 
This is a cr oss-sectional , single visit study t o evaluate the diagnostic ac curacy  of NAATs 
for the detection of N G an d CT from phar yngeal an d rectal s wab s pecimens . Study 
participants w ill have swabs collected from both the rectum and pharynx, f ollowing any  
specimens t aken for clinically indicated t esting .  Eac h of t he swabs f rom eac h anatomic 
location will be tested for both NG and CT using three different NAATs, with a 4th test 
collected and tested as a tiebreaker, if needed. [redacted] Diagnos tic accuracy will be 
calculated with respect to an anatomic site infected status  (ASIS) referenc e standard 
described in Section 3.5. As the reference standard is imperfect, we will report positive 
percent agreement and negative percent agreement in place of s ensitivity and specificity. 
One potential limitation of this study is that all three of the tests in the referenc e standard 
are N AATs. However, all three tests [redacted]. So while, theoretic ally, there may be 
correlation in the errors  produced by the three tests, the v aried molecular targets and the 
different methods of capture, amplification and detection should mitigate this conc ern. 
Endpoints 
•Infection status  for Neisseria gonorrhoeae in the rectum  as determined by each
NAAT
•Infection status for Neisseria gonorrhoeae in the pharynx as determined by each
NAAT
•Infection status for Chlamydia trachomatis  in the rectum as determined by each
NAAT
•Infection status  for Chlamydia trachomatis  in the pharynx  as determined by each
NAAT
•Anatomic Site Infection status as determined by the reference standard (as described
in Section 2.3)
6.3 Sample Size  
For each assay, PPA and NPA35 will be estimated for each of three  diagnostic tests 
defined by pathogen - anatomical site combinations:  
•Neisseria gonorrhoeae in the rectum
•Neisseria gonorrhoeae in the pharynx
•Chlamydia trachomatis  in the rectum
•Chlamydia trachomatis  in the pharynx
Each pat
hogen/anatomic site combination will be evaluated by constructing 95% Score 
confidence interval estimates for PPA  and NPA  and evaluating whether 90% can be ruled 
out by the lower bound of the CI with reasonable confidence.  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
19 NPA is expected to be greater than PPA  and there will be considerably more not -infected 
than infected anatomic site, implying that t here will be greater power for evaluating NPA. 
Thus it will suffice to size the study to evaluate PPA.  
A
ssuming that the true PPA is 96%,13 then 157, 174, and 196 evaluable participants that 
are infected  are needed to have 80%, 85%, and 90% power respectively to demonstrate 
a PPA of greater than 90%. Since all of the participants will contribute to the evaluation of 
all three  pathogen- anatomical site diagnostic tests, it will suffice to size the study for the 
diagnostic test with the lowest expected prevalence (except  CT in the pharynx). The 
study will be more than sufficiently sized for more prevalent disease.  
I
t is expected that the disease prevalence of  NG in the rectum, NG in the pharynx, and 
CT in the rectum will each be greater than 7.5%  in the population under evaluation.13,14,16-
20 Table 3 summarizes the required number of participants to have 80% and 90% 
probabilities of obtaining the 157, 174, and 196 evaluable participants that are disease-
positive to have 80%, 85%, and 90% power when the true prevalence of disease is 7.5%, 10%, and 12.5%.  
Table 3: Sample size required number to have 80% and 90% probabilities of obtaining the 157, 174, and 196 
evaluable participants that are disease- positive when the true prevalence of disease is 7.5%, 10%, and 12.5% in 
order to have 80%, 85%, and 90% power ( two-sided alpha=0.05) to conclude that sensitivity is greater than 90% 
when the true sensitivity is 96%.  
6.4 R
andomization of Swabs  
Randomization will be employed to ensure that the swab order distribution is the same for 
4 tests, the three NAATs  under investigation in the study and the tiebreaker test . SAS 
software (Cary, NC) will be used to generate permuted blocks with a block size of 24, to 
ensure that e ach NAAT and the tiebreaker test would have their swab distributions 
consisting of 1/ 4 being first swabs, 1/ 4 being second swabs, 1/ 4 being third  swabs  and 
1/4 being fourth swabs.  
6.5 Monitoring  
The core protocol team will receive monthly reports monitoring study accrual, study conduct and completeness of data and swab collection.
 Prevalence of 
Disease 
Positive Power  Required 
Disease Positive 
to Obtain Power  Required Sample Size to 
have 80% probability of 
obtaining required 
Disease positive 
participants  Required Sample Size to 
have 90% probability of 
obtaining required 
Disease positive 
participants  
7.5%  80% 157 2250  2325  
85% 174 2475  2575  
90% 196 2775  2875  
10% 80% 157 1700  1750  
85% 174 1860  1925  
90% 196 2100  2150  
12.5%  80% 157 1350  1400  
85% 174 1485  1530  
90% 196 1665  1715  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
20 The study will be reviewed by an independent statistician, who will not have an 
association with the protocol or device companies. The independent statistician will review the progress of the study.
 
Additionally, the study statisticians will prepare reports for the independent statistician that will include baseline summaries (demographics and symptom status) and will 
address issues concerning the viability and appropriate execution of the protocol such as 
accrual, endpoint evaluability, and frequency of tests with equivocal results, invalid 
results, or no results. Issues with specimen collection will be summarized. The independent statistician will also review  and evaluate the rates of disease. Toxicity is not 
expected given the nature of the study.
 
The s
tudy cannot be stopped at the interim for reaching regulatory goals at this time to 
preserve error rates / coverage probability and ensure enough data for subgroup analyses. Since the trial cannot be stopped for attainment of the regulatory goal, no adjustment to confidence levels are necessary.  
Moni
toring design assumptions for appropriate study sizing  
Inf
ection rates will be evaluated to determine whether sample size adjustments are 
warranted. The sample size will not be adjusted based on the observed PPAs and NPAs , 
which will not be reviewed while the study is ongoing,  but may  be adjusted based only on 
the infection rates to ensure enough infected participants to estimate PPAs with desired 
precision. If infection is more prevalent than expected, a smaller sample size may be 
accepted. If however  infection is rare r than anticipated, then increases to sample size will 
be considered. The infection rate will be evaluated approximately every 500 participants  
or every 3 months  after the enrollment of the first participant , whichever comes first . 
6.6 Analyses  
6.6.1 Primary Analyses  
The r
esult for each test will be compared with the ASIS for that anatomic site and 
organism .  For each diagnostic test, PPA  and NPA will be estimated using 95% 
Score confidence intervals. Confidence intervals will be estimated using the 
Score method.34  
In t
he primary analysis,  we will follow the FDA guidance document  for 
incorporating indeterminate  ASIS or test results  for the test under consideration 
that are equivocal.34 Indeterminate ASIS results will be counted against the 
results for the test under consideration, as described in Tables 4 and 5. Tables 4 
and 5 will be presented in the analysis report, showing all combinations of 
Infected/Indeterminate/Not Infected with all outcomes from the test under 
consideration (Positive/Equivocal/Negative/No result  or Invalid) 
If
 the test under consideration has “no result” because the test was not run and 
no attempt was made to test the sample, it will be excluded from the primary 
analysis.  
Table 4.   Use of the ASIS in calculation of the positive and negative percent agreement for 
the Company 2 Assay (Company 2 ) and Company 3 Assay (CT only). 
ASIS  
Infected  Indeterminate * Not infected  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
21 Result of Test 
under 
Consideration ** Positive A D G 
Equivocal  B E H 
Negative  C F I 
No result  Exclude from analysis  
PPA A / (A+B+C+F)  
NPA I / (G + H + I + D)  
*The middle, indeterminate column will be included in the analyses as “Infected” or “Not infected” as
described in the sensitivity analyses below.
**Per the ASIS definition in Section 2.3
Comprehensive s ensitivity analyses will be conducted considering multiple 
scenarios.  These include:  
•Classify indeterminate tests on the basis of symptom status.  Include
indeterminate tests as infected if the participant is symptomatic in that
compartment.  Include indeterminate tests as not i nfected in the
participant is asymptomatic in that compartment.
•Include all ind eterminate tests as i nfected.
oPPA=(A+D)  / (A+B+C+D+E+F)
oNPA=I  / (G+H+I)
•Include all indeterminate tests as not i nfected.
oPPA=A / (A+B+C)
oNPA=(F+I) / (D+E+F+G+H+I)
•Considering indeterminate and equivocal test results as “missing”, with
the assumption of missing at random, and model the missing results.
•Additional sensitivity analyses, including the use of latent class models,
will be explored .  Details will be in the statistical  analysis plan .
Table 5. Use of the A SIS in calculation of the positive and negative percent agr eement for 
the Company 1 Assay (Company 1)  and Company 3 Assay (NG only). 
ASIS  
Infected  Indeterminate * Not infected  
Result of Test 
under 
Consideration ** Positive /Detected  A C E 
Negative /Not 
detected  B D F 
No result  Exclude from analysis  
PPA A / (A+B+D ) 
NPA F / (C+E+F ) 
*The middle, indeterminate column will be included in the analyses as “Infected” or “Not infected” as
described in the sensitivity analyses below.
**Per the ASIS definition in Section 2.3
If
 the test under consideration has “no result” because the test was not run and 
no attempt was made to  test the sample or because of invalid ASIS results it will 
be excluded from the primary analysis . 
Com
prehensive s ensitivity analyses  will be conducted.  These include:  
•Classify indeterminate tests on the basis of symptom status.  Include
indeterminate tests as Infected if the participant is symptomatic in thatcompartment.  Include indeterminate tests as not infected in theparticipant is asymptomatic in that compartment.
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
22 •Include all indeterminate tests as infect ed
oPP
A = (A+C)  / (A+B+C+D)
oNPA = F / (E+F)
•Include all indeterminate tests as not i nfect ed
oPP
A = A / (A+B )
oNPA = (D+F) / (C+D+E+F)
•Additional sensitivity analyses that consider indeterminate results as
“missing”  and utiliz e imputation strategies, and graphical techniques
•Additional sensitivity analyses, including the use of latent class models,will be explored .  De tails will be in the statistical analysis plan .
T
here are pros and cons to the manner in which indeterminates are handled and 
the resulting calculations of PPA and NPA . The primary definition is the most 
conservative but is biased downwards .  If PPA > 90% under this scenario, then 
the conclusion of PPA  > 90% is clear. The second and third  sensitivity analys es 
count  indeterminates (treat all as infected or not infected, respectively ) but may 
not be conservative for calculations of PPA and NPA.  
6.6.2 S
econdary Analyses  
Global Analyses  
F
or each diagnostic test:  
•P
ositive and negative predictive values (PPV and NPV) will be
estimated. PPV and NPV will each be plotted as a function of prevalenc e
(
point estimates and 95% pointwise confidence bands)
•Positive and negative likelihood ratios will be estimated using 95% Score
c
onfidence intervals
•A sensitivity analysis will include calculating equivocal predictive valuesand likelihood ratios
•An additional sensitivity analysis will calculate PPV, NPV, and positiv
e
and 
negative likelihood ratios for the sensitivity analyses wher e
i
ndeterminates  are counted as Infected and Not Infected
Subgroup Analyses  
F
or each of the three diagnostic tests, subgroup analyses will be conducted for 
males, females, symptomatic participants, and asymptomatic participants  by 
pathogen and anatomic site. The 95% Score confidence interval estimates of 
PPA and NPA  will be displayed using forest plots (one plot per tes t). The 95% 
Score confidence interval estimates of positive and negative likelihood ratios will 
be displayed using forest plots (one plot per test). PPVs and NPVs  will each be 
plotted as a function of prevalence (point estimates and pointwise confidence 
bands).  
T
he sensitivity analyses where indeterminates are counted as Infected and Not 
Infected will be repeated for the four subgroup analyses.  
Exploratory Analysis  
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
23 Developing methods for diagnostic benefit:risk analyses (e.g., diagnostic yield) will 
be applied.  
7.0 Quality Control  
 
 7.1 Quality Controls and Study Monitoring  
 
The ARLG  will provide direct access to the dataset for the purposes of monitoring and 
auditing by the DCRI, Harvard School of Public Health  and inspection by local and 
regulatory authorities. The local site PI will ensure that study personnel are appropriately 
trained and applicable documentations are maintained.   
 
The DCRI will implement a Quality Plan to ensure that protocol training, data  quality and 
data security are being undertaken.   
 
7.2 Source Documents and Access to Source Data  
 
Source documents will not be removed from the sites.  Study monitoring will occur 
remotely , unless there are quality or performance concerns at a site, in which case an on-
site visit will occur.  
 
8.0 Ethics  / Protection of Human Subjects  
 
8.1 Ethical Standards  
 
The investigator will ensure that the study will be conducted in accordance with all 
applicable national, regional, and local regulations.  
 
8.2 Institutional Review Board  and Informed Consent  
 
 This protocol and any subsequent modifications must be reviewed and approved by the 
IRB responsible for oversight of the study , as listed on its FWA .  To minimize risks 
associated with loss of privacy and loss of confidentiality, oral informed consent will be 
obtained from the subject.  The informed consent  process  will describe the purpose of the 
study, the procedures to be followed, and the risks and benefits of participation.  A copy 
of a patient information form  may be given to the subject  (per local policy) .   
 
8.3 Subject Confidentiality  
 
Subjects will have code numbers and will not be identified by name. Subject 
confidentiality is strictly held in trust by the participating investigators, their staff, and the 
Sponsor(s) and their agents.   
 
The study protocol, documentation, data, and all other information generated will be held 
in strict confidence.  No information concerning the study or the data will be released to 
any unauthorized third party without prior written approval of the ARLG . 
 
All information provided by the ARLG  and all data and information generated by the 
participating clinical site as part of the trial will be kept confidential by the site PI  and 
other study personnel. This information and data will not be used by the site PI or other 
study personnel for any purpose other than conducting the trial. These restrictions do not 
apply to: (1) information which becomes publicly available through no fault of the site 
principal investigator or other study personnel; (2) information which is necessary to 
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
24 disclose in confidence to an IRB solely for the evaluation of the trial (3) information which 
is necessary to disclose in order to provide appropriate medical care to a study subject; 
or (4) study results which may be publ ished as descr ibed in Section 10.  
 
The study monitor or other authorized representatives of the sponsor may inspect all 
documents and records required to be maintained by the PI . The clinical study site will 
permit access to such records.  
  
All laboratory specimens, case report form  data, reports and other records will be 
identified only by a coded number to maintain subject confidentiality.     
 
8.4 Specimen Handling  
 
Specimens  will be collected for this study  and will be maintained by the ARLG at least 
until all companies have received their FDA approval for their assay.   
 
Use of samples for future research will be part of the consent process. There will not be 
any opt-in/opt -out language.  Samples may be shared with other investigators at other 
institutions. No human genetic tests will be performed on samples. Each sample will be 
encoded (labeled) only with a barcode and a unique tracking number to protect subject’s 
confidentiality.  
 
There are no benefits to subjects in the collection, storage and subsequent research use 
of specimens. Because the subject enrollment will be done anonymously, r eports about 
future research done with subject’s samples will  NOT be reported into their health 
recor ds.  
 
9.0 Data Handling and Record Keeping  
 
 9.1 Data Collection  
 
This study will use eClinical OS  (eCOS) , a Web- based e- CRF database used by the 
DCRI.  The investigator's site staff who will be entering data will receive training on the 
system, after which each person will be issued a unique user identification  ID and 
password.  
 
For security reasons, and in compliance with regulatory guidelines, it is imperative that 
only the persons who own the user IDs and passwords access the system using their 
own unique access codes. Access codes are nontransferable. Site personnel who have 
not undergone training may not use the system and will not be issued a user ID and 
password until appropriate training is completed.  
 
 9.2 Inspection of Records  
 
The DCRI  will implement  a Quality  Plan to, at a minimum,  ensure that activities  
proposed  by the PI to ensure protocol  training,  data quality  and data security  are being  
undertaken.  
 
Source Documents  and Access to Source Data  
 
Source documents  will not be removed  from the sites.   
 
 9.3 Retention of Records  
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
25  
Records will be  maintained during the investigation and for a period of 2 years after the 
latter of the following dates: The date on which the investigation is terminated or 
completed, or the date that the records are no longer required for purposes of 
supporting a premarket approval application or a notice of completion of a product 
development protocol.  Records may not be destroyed without the prior approval of the 
ARLG.  
 
 9.4 Confidentiality  
 
The study  protocol,  documentation,  data,  and all other  information generated by this 
study  will be maintained in a secure  manner  and will be kept confidential  as required by 
law. 
 
The EDC  database  (eClinical  OS data)  used by the DCRI will be hosted by Merge  which  
uses  a Peak  10 datacenter  located in Morrisville  NC. Database access will be limited  to 
study  personnel  who are issued a unique user identification and password.  Data  will 
be entered at each  site by study  personnel.  No information concerning the study  or the 
data will be released  to any third party  without  prior written  approval  of the Sponsor.  
Study  records  may be reviewed in order  to meet  federal  or state  regulations.  
Reviewers  may include  the IRBs,  the DCRI  and the NIH. 
 
10.0 Publication Policy   
 
Following completion of the study, the investigator may publish the results of this research in a 
scientific journal under the oversight of the Publication Committee of the ARLG.  
 
The ARLG Publication Committee comprises representatives of the network cor es, thought -
leaders, statistics and data management  center (SDMC), and is responsible for generation and 
coordination of the publications that report scientific findings of the network. All public 
presentations (abstracts, manuscripts, slides and text of oral or other presentations, and text of 
any transmi ssion through any electronic media) by participating investigators, participating 
institutions, SDMC, and ARLG that use ARLG data and are intended to represent the ARLG or 
are supported by the ARLG will be reviewed by the Publication Committee per the Publ ication 
Committee charter and must include the following statement : “Research reported in this 
publication was supported by the National Institute Of Allergy And Infectious Diseases of the 
National Institutes of Health under Award Number UM1AI104681. The c ontent is solely the 
responsibility of the authors and does not necessarily represent the official views of the National 
Institutes of Health.”  
 
The Publication Committee will ensure  that the study results are presented by experts in the field 
that have working knowledge of the study design, implementation, data synthesis/analysis, and 
interpretation. The committee goals are to ensure that any confidential or proprietary information 
is protected, and that all appropriate statistical analyses have been included.  
 
The ARLG Publication Committee will adhere to the trials registration policy adopted by the 
International Committee of Medical Journal Editors (ICMJE) member journals. This policy 
requires that all applicable clinical trials be registered in a publi c trials registry such as 
ClinicalTrials.gov , which is sponsored by the National Library of Medicine. Other biomedical 
journals are considering adopting similar policies.  
 
In June 2007,  the ICMJE adopted the WHO's definition of clinical trial: "any research study that 
prospectively assigns human participants or groups of humans to one or more health- related 
interventions to evaluate the effects on health outcomes."  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
26 •H
ealth- related interventions include any intervention used to modify a biomedical or
health- related outcome (for example, drugs, surgical procedures, devices, behavioral
treatments, dietary interventions, and process -of-care changes).
•Health outcomes include any biomedical or health- related measures obtained in patients
or participants, including pharmacokinetic measures and adverse events.
A
ll investigators funded by the NIH must submit or have submitted for them to the National 
Library of Medicine’s PubMed Central an electronic version of  their final, peer -reviewed 
manuscripts upon acceptance for publication, to be made publicly available no later than 12 
months after the official date of publication. The NIH Public Access Policy  ensures the public has 
access to the published results of NIH -funded research. It requires investigators to submit final 
peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed 
Central  upon acceptance for publication. Further, the policy stipulates that these papers  must be 
accessible to the public on PubMed Central no later than 12 months after publication.  
R
efer to: http://publicaccess.nih.gov/  
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
27 11.0 References  
1. Company 1 Assay package insert. Vol. XXX, Rev .
2. Company 2 Assay package insert. Vol. XXX Rev .
3. Company 3 Assay package insert. Vol. Ref XXX .
4. WHO. Global Inc idence and prevalence of selec ted curable sexually transmitted  
infections.  (WHO Department of Reproductive Health and Research, 2008).
5. CDC. Sexually Transmitted Disease Surveillance.  (2013).
6. Liu, B., et al. Chlamydia and gonorrhoea infections and the risk of adverse obstetric  
outcomes: a retrospective cohort study. Sex Transm Infec t 89, 672-6 78 (2013).
7. O'Brien, J.P., Goldenberg, D.L. & Rice, P.A. Disseminated gonococcal infection: a  
prospective analysis  of 49 patients and a review of pathophysiology  and immune  
mechanisms. Medicine 62, 395-4 06 (1983).
8. Westrom, L., Joesoef, R., Reynolds , G., Hagdu, A. & Thompson, S.E. Pelvic  
inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopic ally 
verified disease and 657 control women with normal laparoscopic  results. Sex Trans m 
Dis 19, 185-1 92 (1992).
9. Rottingen, J.A., Cameron, D.W. & Garnett, G.P. A systematic review of the  
epidemiologic interactions  between classic sexually transmitted dis eases and HIV: how  
much really is known? Sex Transm Dis  28, 579-5 97 (2001).
10. Deguchi, T., Yasuda, M. & Ito, S. Management of pharyngeal gonorrhea is crucial to  
prevent the emergence and spread of antibiotic -resistant Neis seria gonorrhoeae.  
Antimicrob Agents Chemother. 56, 4039-4 040 (2012).
11. Work owski, K.A. & Bolan, G.A. Sexually transmitted diseases treatment guidelines , 
2015. MMWR Recomm Rep 64, 1-1 37 (2015).
12. Zakher, B., Cantor, A.G., Pappas, M., Daeges, M. & Nelson, H.D. Screening for  
gonorrhea and chlamydia: a systematic review for the U.S. Preventive Services Tas k 
Force. Ann Intern Med 161, 884-8 93 (2014).
13. Ota, K., Tamari, I. & Smieja, M. Detection of Neis seria gonorrhoeae and Chlamydia  
trachomatis in phary ngeal and rectal specimens using the BD ProbeTec ET system, the  
Gen-P robe Aptima Combo 2 assay and c ulture. Sexually Transmitted Infections 85, 
182-1 86 (2009).
14. Schachter, J., Moncada, J. & Liska, S. Nucleic acid amplific ation tests in the diagnosis  of 
chlamydial and gonococcal infections of the oropharyngx and rectum in men who have  
sex with men. Sexually Transmitted Diseases 35, 637-6 42 (2008).
15. Trebach, J.D., Chaulk, C.P., Page, K.R., Tuddenham, S. & Ghanem, K.G. Neisseria  
gonorrhoeae and Chlamydia trac homatis among women reporting extragenital  
exposures. Sex Trans m Dis 42, 233-2 39 (2015).
16. Bachmann, L., Johnson, R. & Cheng, H. Nucleic acid amplic ations test for diagnosis of  
Neisseria gonorrhoeae and Chlamydia trac homatis rectal infections . Journal of Clinical  
Microbiology 48, 1827-1 832 (2010).
17. Cosentino, L.A., et al. Use of nucleic acid amplification testing for diagnosis of anorectal  
sexually transmitted infections. J Clin Microbiol 50, 2005-2 008 (2012).
18. Geelen, T.H., et al. Performance of cobas(R) 4800 and m2000 real-t ime assays for  
detection of Chlamydia trachomatis and Neisseria gonorrhoeae in rectal and self-
collec ted vaginal specimen. Diagn Microbiol Infect Dis  77, 101-1 05 (2013).
19. Moncada, J ., Schachter, J., Liska, S., Shayevich, C. & Klausner, J.D. Evaluation of self-
collec ted glans and rectal swabs  from men who hav e sex with men for detection of
pNAAT           Version 4.0  
     December 4th, 2017  
 ____________________________________________________________________________________________  
28 Chlamydia trachomatis  and Neisseria gonorrhoeae by use of nucleic acid amplification 
tests. J Clin Microbiol 47, 1657- 1662 (2009).  
20. Perry, M.D., Jones, R.N. & Corden, S.A. Is confirmatory testing of Roche cobas  4800
C
T/NG test Neisseria gonorrhoeae  positive samples required? Comparison of the Roc he
c
obas 4800 CT/NG test with an opa/pap duplex assay for the detection of N
gonor
rhoeae . Sex Transm Infect  90, 303- 308 (2014).
21. Harryman, L. , et al. Comparative performance of culture using swabs transported i n
A
mies medium and the Aptima Combo 2 nucleic acid amplification test in detection of
Neisseria gonorrhoeae from genital and extra -genital sites: a retrospective study. Se x
Tr
ansm Infect  88, 27-31 (2012).
22. Walsh, A., Rourke, F.O. & Crowley, B. Molecular detection and confirmation of Neisseri a
g
onorrhoeae in urogenital and extragenital specimens using the Abbott CT/NG
RealTime assay and an in- house assay targeting the porA pseudogene. Eur J Clin
Microbiol Inf ect Dis  30, 561 -567 (2011).
23. Goldenberg, S., Finn, J., Sedudzi, E., White, J. & Tong, C. Performance of the
GenExpert CT/NG Assay compared to that of the Aptima AC2 Assay for Detection of
Rectal Chlamydia trachomatis  and Neisseria gonorrhoeae  by use of Residual Aptim a
S
amples. Journal of Clinical Microbiology  50, 3867- 3869 (2012).
24. Cosentino, L. , et al. A Validation Study of the Cepheid Xpert CT/NG for detecti ng
C
hlamydia trachomatis  and Neisseria gonorrhoeae in Rectal Samples. Sex Transm
Infect  91, A1-A258 (2015).
25. CDC. Recommendations for the Laboratory -Based Detection of Chlamydia trachomatis
and Neisseria gonorrhoeae.  (2014).
26. Gen- Probe. APTIMA Chlamydia trachomatis Assay. Vol. 501799 Revision D (San Diego,
2012).
27. Gen- Probe. APTIMA Neisseria gonorrhoeae Assay. Vol. 502486 Revision A 73 (San
Diego, 2011).
28. Boyadzhyan, B., Yashina, T., Yatabe, J.H., Patnaik, M. & Hill, C.S. Comparison of theAPTIMA CT and GC assays with the APTIMA combo 2 assay, the Abbott LCx assay,and direct fluorescent -antibody and culture assays for detection of Chlamydi
a
t
rachomatis and Neisseria gonorrhoeae. J Clin Microbiol 42, 3089- 3093 (2004).
29. Chernesky, M.A. , et al.  Ability of new APTIMA CT and APTIMA GC assays to detect
Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J
Clin
 Microbiol 43, 127- 131 (2005).
30. Moncada, J., Donegan, E. & Schachter, J. Evaluation of CDC- recommen ded
appr
oaches for confirmatory testing of positive Neisseria gonorrhoeae nucleic aci d
a
mplification t est results. J Clin Microbiol 46, 1614- 1619 (2008).
31. Tabrizi, S.N. , et al. Evaluation of six commercial nucleic acid amplification tests for
detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol 49,
3610
-3615 (2011).
32. BD. B D ProbeTec Chlamydia trachomatis  (CT) Qx Amplified DNA Assay package insert.
Vol. 8081408 (2010).
33. BD. BD ProbeTec Neisseria gonorrhoeae (GC) Qx Amplified DNA Assay package insert.
Vol. 8081409 (2010).
34. FDA. Establishing the performance characteristics of in vivo  diagnostics devices for
Chlamydia trachomatis  and/or Neisseria gonorrhoeae: screening and diagnostic testing.
(2011).
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
29 35. FDA. Statistical Guidance on Reporting Results from Studies Evaluating D iagnostic 
Tests . (2007).  
  
pNAAT                    Version 4.0  
              December 4th, 2017  
 
 ____________________________________________________________________________________________  
30  
APPENDIX A  - Schedule of Events  
 
 
 Enrollment  
Clinical Evaluations  
Review of eligibility  X 
Verbal consent  X 
Baseline CRFs  X 
Collection of Specimens  
Rectal swabs  X 
Pharyngeal swabs  X 
 